AstraZeneca’s Tezspire approved in the EU for patients with severe asthma

AstraZeneca’s Tezspire – also known as Tezepelumab – has been approved in the EU as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.